Back to Top

Information For Authors

Instructions for Authors

The Journal of Child and Adolescent Psychopharmacology is published 10 times a year.  It focuses on Child and Adolescent Psychopharmacology and those aspects of Child and Adolescent Psychiatry, Neurology, Pediatrics, and the neurosciences that are clearly related to this. The Journal publishes papers encompassing investigative research, treatment techniques, basic sciences, health policy and education, focused reviews and clinical case reports or conferences.

Manuscripts must be submitted online using the following url: http://mc.manuscriptcentral.com/jcap. Please read all the instructions to authors before submitting.

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

Copyright Agreement Form

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal. 

Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form.  It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.

FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM MAY RESULT IN A DELAY OF PUBLICATION.

The corresponding author is responsible for communicating with coauthors to make sure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.

GUIDELINES

Deviations from these Instructions for Authors will generally result in a return of the manuscript for correction before review.

FORMATS

The Journal will consider original research papers, brief reports, reviews, and letters to the editors.

Original research articles and brief reports should have an Abstract, Introduction, Methods, Results, Discussion, Conclusions, Clinical Significance, Disclosures, Acknowledgments, if needed, References, Tables and Figures, and Legends. One subsection level is allowed.

Brief reports should be no more than 10 manuscript pages including references and disclosures, and no more than 2 tables (or figures). Case reports of 5 or more cases can be submitted as a brief report.

Case reports of 1-4 cases must be submitted as a Letter to the Editor.

Letters to the Editor(s) are welcomed, but with a 500-word limit and no more than one (1) table OR figure, and with a maximum of four (4) references.

 

MANUSCRIPT SUBMISSION AND REVIEW

A submitted paper (or any essential part) must not be published or simultaneously submitted to other publications prior to its appearance in this Journal (except for abstracts or press reports from scientific meetings).

Submissions to the Journal will undergo peer review.  Manuscripts may be edited for clarity, conciseness, grammar, and conformity to Journal style. Authors will receive page proofs before publication.

Authors should include a minimum of 3 to 5 preferred reviewers (with email addresses) whom they think are particularly expert in the subject of their paper. This information should be provided in the preferred reviewer section during the online submission process through manuscript central.

Accepted manuscripts become the permanent property of the Journal, and may be republished elsewhere only with the written permission of the publisher. There are no page charges.

PREPARATION OF MANUSCRIPTS

All text files should be submitted in Word files. Do not submit PDFs.

Author Disclosure


All authors must disclose all institutional or corporate/commercial relationships going back 36 months, or to the time of the data collection if the data were collected longer than 3 years ago, that might pose a conflict of interest. The Journal should also be informed if any conflicts of interest arise after submission and before publication of the paper. Institutional affiliations and funding sources that supported the work (from any grant, funding source, or commercial interest/pharmaceutical company) are to be indicated on the title page.

The Author Disclosure section is to be uploaded along with your manuscript as a separate Word file. The disclosure is required for submission. If the authors have nothing to disclose, state this in the file for each author.

The Disclosures should include all corporate/commercial relationships that might pose a conflict of interest, e.g., all of the authors' relationshps with all pharmaceutical companies. This includes such things as all consultancies, honoraria, stock ownership, gifts, free or reimbursed travel/ vacations, equity interests, arrangements regarding patents or other vested interests, etc. (not just those immediately related to this specific paper or to the pharmaceutical company sponsoring the submitted paper). If a specific author has no financial relationships with any pharmaceutical company, it must be so stated in the Disclosure section. If the study was supported by a pharmaceutical company, it must be stated in the Disclosure section who analyzed the data and who wrote the paper (the authors or a medical writer). Papers submitted without an Author Disclosure section will not be reviewed.

First Page

On the first page, give the full title of the article, full name(s) and highest academic degree(s) of all author(s), the name of the department and institution where the work was done, and other institutional affiliation(s) and title(s).  State the names and affiliations of statistical consultants. Support received from any grant, funding source, or commercial in-terest should be indicated. Also, give name, address, telephone, and email address of the corresponding author and of the author who will receive requests for reprints. Provide a running title that is less than 45 characters. Include an abstract. Please number all pages consecutively.

Titles

Whenever possible, the titles of papers should provide specific information rather than merely suggest a general topic. Many readers who scan the medical literature in indexing sources see only the titles, and should receive information by scanning. Titles in the Journal should be self-explanatory and self-contained. Rather than a title such as "Conduct Disorder and ADHD," use "Conduct Disorder Is Present in 70% of Children with Attention-Deficit/Hyperactivity Disorder." Please avoid two-part titles and abbreviations.

Abstracts

All submissions, except letters, must be accompanied by a structured abstract of less than 300 words. The abstract must have the following four sections: Objectives, Methods, Results, and Conclusion.  The abstract should be fully understood on its own, without any reference to the text itself. Statements that give generalized accounts, such as "Implications will be discussed," are not helpful: Indicate concisely what are seen as the most important implications.

Tables, Figures, and Illustrations

Figures:

  • Prepare each figure as individual .TIFF or .EPS file
  • Do NOT embed figures and/or images within the manuscript file.
  • Do NOT submit figures in Word, PowerPoint, PDF, Bitmap, .JPEG, or Excel.
  • Line illustrations must be submitted at 900 DPI.
  • Halftones and color should be submitted at a minimum of 300 dpi.
  • Color art must be saved as CMYK - not RGB. (N.B., If RGB files are submitted, the files will be converted to CYMK and some color variation will occur.)
  • Black and white art must be submitted as grayscale – not RGB
  • For direction on conerting a Power Point slide to acceptable format go to: www.liebertpub.com/MEDIA/pdf/ppconvert.pdf

 Tables:

  • Prepare and save each table in individual .doc or .docx files.
  • Do not include tables in the main manuscript text file.
  • Do not embed tables within the text.
  • Include a table number and a title for each supplied table. 
  • Use Arabic numerals to number tables.
  • Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences.
  • Define all acronyms used within the body of the table in table footnotes.
  • All other types of table footnotes should be designated using superscript letters, not symbols.
  • Name all table files in English and use only alphanumeric characters.  Do not use symbols, dots, lines, or dashes.
  • Table file names should be formatted with first author’s last name and the figure number. (Ex:  SmithTable1)
  • Upload individual table file under the “Table” file designation.

Supplementary Information:

When appropriate, we encourage the judicious use of online-only supplementary information (SI). All information/data in the SI should be referred to in the article text, including reference to specific tables and figures in the SI. Upload supplementary tables, figures, and legends as separate files, either as “supplementary file” or “supplementary file for review only.” The manuscript should be written so that the paper which appears in the printed journal contains all data which are key to the conclusions and important for the reader to have direct access to when reading the paper. Other supporting data and text are appropriate for the supplementary section.  NOTE: Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.

Statistics

In research involving statistical analysis, please include the following: (a) the hypotheses in clearly stated form, (b) the statistical tests used, cited by name, for each data set, (c) the use of either one-tailed or two-tailed tests, and (d) the test value, degree(s) of freedom, and probability for every significant and important nonsignificant result. Use standard deviations rather than standard errors of the mean. For novel or not well-known tests, provide a citation.

Clinical Significance

Each original research article, review, or brief report should include a "Clinical Significance," just before the Author Disclosure statement.  This section requires one brief paragraph that will communicate the clinical importance of the work, and its relevancy to the scientific community, in a few short sentences.


References

Authors maintain responsibility for the accuracy of their citations. Text citations will appear preferably at the end of sentences, and will indicate first (A 1990), first and second (A and B 1990), or first plus (A plus all coauthors 1990) authors, with year of publication and without a comma.  Citations in the reference section should list all coauthors (et al. is not permitted in the reference list), be alphabetized rather than numbered, and multiple citations to one author should be placed in chronological sequence; the list should be double spaced, with each reference separated by a single line of space.  Any references published in a foreign language should be followed by an English translation in brackets. Do not indicate issue numbers unless issues are not sequentially paginated. Credit for figures and illustrations should be given in captions. Personal communications, unpublished data, and manuscripts "in preparation" or "submitted for publication" may be incorporated into the text but not in the reference list. Abbreviations will follow the style of Medline. Please follow the style of these examples:

Riddle MA, Hardin MT, King R, Scahill L, Woolston
JL: Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45-48, 1990.
Courchesne E, Yeung-Courchesne R: Event-related brain potentials. In: Assessment and Diagnosis in Child Psy-chopathology. Edited by Rutter M, Tuma AH, Lann IS. New York, Guilford Press, 1988, pp 264-299.
Adams GR, Montemayor R, Gullotta TP (eds): Biology of Adolescent Behavior and Development. Newbury Park (California), Sage Publications, 1989.
Geller B: A double-blind placebo-controlled study of nortriptyline in adolescents with major depression. Washington (DC), National Institute of Mental Health, New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, 1989 (abstract).

 

Abbreviations and Medication Names

Weights, heights, and other measurements should be in the metric system.  When an abbreviation or acronym is first used in the abstract and in the text, it must be spelled out in full and followed by the abbreviation in parentheses. When an abbreviation or acronym is used in each table and figure, it should be spelled out in full in the table footnote or figure citation. For standard abbreviations, consult the Style Manual for Biologic Journals, 4th edition (American Institute of Biological Sciences, 1401 Wilson Blvd, Arlington, VA 22209).

 

Identify medications by generic name. A brand name may also be placed in parentheses; but since brand names are generally used only in a single country, specify the locale in which the proprietary name is used. Proprietary names, but not generic or chemical names, should have initial capital letters. For materials and devices, describe by nonproprietary name, and then indicate (in parentheses) brand name, manufacturer's name, city, state, and country. Be certain to use the brand names of medications or products that are experimental or that are crucial to the replication or interpretation of the study.

Permissions

Materials taken from other sources must be accompanied by written statements from both author and publisher giving permission for reproduction to the Journal. If clearance is also required by the author's institution, these statements should be provided with the manuscript. For papers in press, unpublished data, and personal communications, submit written permission from the first author along with the manuscript.

Patient Confidentiality

Strict anonymity of patients must be maintained. Do not use actual names, initials, dates, or hospital numbers. In describing the personal characteristics of a patient, disguise any potentially identifying information. [The only exception is a photograph of an identifiable patient, for whom written permission for publication has been obtained.]

Informed Consent and Assent

For clinical reports, an explicit description of the informed consent procedures involving both parents, as well as the assent provided by younger adolescents and children, is required in the Methods section. Agreement is required both for consent to research and permission to publish.

Human or Animal Experimentation

Reports of research involving experimental subjects should be accompanied by a statement indicating approval by the Institutional Review Board (or Institutional Animal Care and Use Committee).

Acknowledgments

Thanking individuals involved in the scientific or technical aspects of manuscript preparation should not exceed four typed lines.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

DISCLAIMER

The originality and accuracy of data, statements, and opinions in the Journal are the responsibility and liability of the individual contributors (and advertisers). These statements do not necessarily represent the views of the editors, the publisher, or the Journal.

PUBLISHER

The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; fax: (914) 740-2101; e-mail: info@liebertpub.com internet: www.liebertpub.com

 

Our dynamic Author Benefits Program provides you with end-to-end benefits that ensure your hard work pays off and your published manuscript gets the attention it deserves not just upon publication, but permanently.

Liebert Open Access

Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option

Explore Liebert Open Access

Does your research funder have an open access mandate or would you like to expand the dissemination of your research?

The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.

The benefits of Liebert Open Access include:

  • High visibility; open access articles are freely available online upon publication
  • You retain copyright with the open access license allowing broad dissemination of your research
  • You can freely share your article in repositories and research networks without restrictions
  • Easy compliance with open access mandates
  • Rigorous editorial and peer-review
  • Targeted email announcement featuring a direct link to article

Identification and Marketing

Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.

Copyright and Licensing

If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.

Ordering Open Access

Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email openaccess@liebertpub.com.

Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form.  You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.

Publishing biomedical or biotechnology research?

Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.

 *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

 

Browse journals in the Liebert Open Access portfolio:

JOURNAL FEES

  • There are no submission fees to Journal of Child and Adolescent Psychopharmacology.
  • There no page charges for Journal of Child and Adolescent Psychopharmacology.
  • Please contact AuthorBenefits@liebertpub.com for costs for publishing images in color.
  • Open Access and Creative Commons licensing options are available. Contact our Open Access Manager for more information.
  • For pricing and purchasing reprints, contact our Reprints Manager.
  • Any fees collected or payments associated with a submitted and/or published paper that is subsequently withdrawn and/or retracted for any reason are non-refundable.

All Mary Ann Liebert, Inc. journals follow the standards, guidelines, and best practices set forth by the -Committee on Publication Ethics (COPE; publicationethics.org), the International Committee of Journal Medical Editors (ICJME; www.icmje.org), the World Medical Association (WMA); www.wma.net) and the American Medical Association (www.ama-assn.org).

Journal of Child and Adolescent Psychopharmacology is a single-blinded peer-reviewed journal. All submissions are subject to peer review. Upon submission, manuscripts are assessed by an editor for suitability for the journal.  For those that are deemed suitable, a minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper should be accepted, require revision, or is unacceptable for publication.

Confidentiality in Peer Review

Editors and reviewers must maintain strict confidentiality of manuscripts during the peer-review process. Sharing a manuscript in whole or in part, outside the scope of what is necessary for assessment, is impermissible prior to an accepted manuscript's official publication date.

Sharing of Materials during Peer Review

Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.

Papers Authored by the Editor-in-Chief and/or Associate Editors

The Editor-in-Chief and Associate Editors will recuse themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest.

Self-Citation and Self-Plagiarism

Journal of Child and Adolescent Psychopharmacology is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works. (Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any submitted manuscript.)

Time in Review

Journal of Child and Adolescent Psychopharmacology aims to maintain a short, but thorough peer-review process. The average time in review is 35 days. However, the Editor(s) will strive to expedite manuscript handling if/when special circumstances dictate.

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.
 

AUTHORSHIP

Definition of Authorship

Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Non-Author Contributors

Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.

For further information, visit the International Committee of Medical Journal Editors’ website at: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

ORCID IDs

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

AUTHORSHIP LIMIT

There is a limit of 35 of authors permitted on a single submission, but in cases where there are 20 or more co-authors, Journal of Child and Adolescent Psychopharmacology recommends that a collective group or consortium name be provided and the individual authors listed in the Acknowledgements.

CORRESPONDING AUTHOR**

One author should be designated as the corresponding author who will be responsible for communication between the authors and the journal editorial office(s) and publisher. This individual will be responsible for ensuring all authors submit copyright forms and coordinating and responding to page proofs, as well as any managing any other necessary contact during the peer review and/or production processes.

**NOTE: Due to configuration restraints, the submission system permits only one author to be identified as the corresponding author of record. However, we recognize that some submissions call for more than one corresponding author to be noted. In such cases, select one author to be the main point of contact and/or corresponding author for all communications regarding the peer review process of the paper, but on the title page of the manuscript, designate additional co-corresponding authors by including an asterisk after the authors' names in the byline, and include an accompanying footnote on the title page that reads, "*Co-corresponding authors."  Please ensure that the title page of the submission page carries the full affiliation details and email addresses of all authors who should be noted as a corresponding author. If the paper is accepted for publication, the full contact information for all desginated co-authors will be listed at the end of the article as per usual journal style.

WORKING GROUPS / TEAM AUTHORSHIP

Working Groups or Teams may be listed in the manuscript byline, but the entire listing of names and affiliations should be included in the acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.

VARIATIONS OF AUTHORSHIP

It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include an asterisk (*) next to the authors' names who are considered as first authors. Include a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."

CHANGES IN AUTHORSHIP

Changes in authorship after submission or acceptance of a paper are strongly discouraged, but the editorial leadership recognizes that in certain circumstances, it may be required. The journal's policy for such cases is as follows:

  • A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
  • Authorship may be altered after submission or acceptance of a paper ONLY with the expressed written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher can provide a form for this, if needed.
  • Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
  • There is a one-year post-publication statute of limitation on requests for alterations in authorship.
  • Post-publication changes or alterations to conference abstracts are prohibited.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

EXCLUSIVITY

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference abstract.  If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission.

USE OF ENGLISH LANGUAGE

All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Journal of Child and Adolescent Psychopharmacology. For authors whose native language is not English, we recommend using a service that will aid in the translation and rewriting of material into correct and proper English usage. The Publisher offers this service for a fee prior to official submission. For more information, please contact: Editing@liebertpub.com Please note that employing the use of the Publisher's service is not required and using it, or any other language editing service, does not guarantee acceptance of any paper. All submissions are subject to peer review.

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

SELF-CITATION AND SELF-PLAGIARISM

Journal of Child and Adolescent Psychopharmacology is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

AFFILIATIONS

Authors should identify as their institution(s) the facility where the work was performed and executed.  Changes in an author’s affiliation after the work was completed but prior to the submission or publication of the manuscript should be noted by including an asterisk as a superscript to the name in the author listing, as well as a corresponding footnote on the title page indicating “Current Address” listing the new affiliation.   Corrections to affiliations or contact information due to relocation after publication is not permitted.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(as described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

ETHICS OF EXPERIMENTATION

All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/).

ETHICAL TREATMENT OF ANIMALS

All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

For further information, consult the World Medical Association’s website: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(as described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

COPYRIGHT AGREEMENT FORM

Upon acceptance of any manuscript, all authors will receive an email with detailed instructions and a unique, author-specific link to access and complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications. FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY OF PUBLICATION. The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright. Copyright forms may also be completed by logging in to the system using an author's credentials. After logging on, click on Author Center and complete the forms located under "Manuscripts I Have Coauthored."

Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc., unless alternate arrangements are made prior to publication, including CC-BY licensing (see below). By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.

OPEN ACCESS / CC-BY LICENSING

Journal of Child and Adolescent Psychopharmacology is a subscription-based peer-reviewed journal with Open Access options. Creative Commons CC-BY and CC-BY-NC licensing is available for all articles published open access for a standard Article Processing Charge (APC) of $3,200.00 USD. Please contact our Open Access Manager to order open access for your article. Learn more about open access publishing on our website.

PERMISSIONS

When reproducing copyrighted material such as figures, tables, or excerpted text, the author(s) of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission.  Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.

REUSE OF MATERIAL POSTED ON SOCIAL MEDIA

As material posted on social media platforms is usually not peer-reviewed content, it is not permitted as an official citation and/or reference.

Mary Ann Liebert, Inc., publishers permits the use of accepted pre-published manuscripts for the sole purpose of pitching to news organizations under strict embargo, and with the approval of and expressed collaboration with the publisher. A watermarked PDF version of the article (not a Word document or any other editable version) may be shared only with named, personal contacts at trusted news sources upon request. News sources must be informed upon delivery of the PDF that the manuscript is for reference-only purposes and can be used only in preparation of their news coverage of the article. It is strictly prohibited to publicly share, post, or otherwise distribute the PDF in any media format. Upon official publication of the article, news organizations must link directly to the published article on the publisher’s journal website. To coordinate publication timing and press efforts, please contact the Director of Marketing, Kathryn Ryan (kryan@liebertpub.com).

DATA SHARING

Journal of Child and Adolescent Psychopharmacology strongly advocates the sharing and archiving of the data and any other artifacts that define and support the results stated in a manuscript in a suitable public repository (in accordance with valid privacy, legal, and ethical guidelines). A data availability statement should be included in the manuscript (in the Methods section or as a separate section at the end of the manuscript), describing the location of the data, with details on how it can be accessed as well as any licensing information. If the data is not publicly available or accessible, that information should also be provided.

Datasets should be cited in the reference list by Author (Year). Title. Publisher. Identifier/DOI.

Important: Please check with your funding agencies to ensure that are you following their data sharing polices. If your funding agency has additional requirements exceeding our policy, you must follow the requirements of your funder.

PREPRINT SERVERS

A preprint is a complete draft of a research paper that is shared on a public preprint server prior to submission to a journal for peer review.
 
Mary Ann Liebert, Inc., allows for papers that were previously deposited on preprint servers to be submitted to our journals, with the proviso that the author updates any preprint versions with a link to the final published article.  All submissions are subject to peer review and allowing the submission of preprint manuscripts does not guarantee publication in any Mary Ann Liebert, Inc., journal.
 
The submitting author of a paper that was previously deposited to a preprint server should include a disclosure on the title page of the manuscript indicating the name and website of the server and include the DOI number of the preprint.
 
Referencing/citing non-peer-reviewed material that is found on any preprint server is generally discouraged by Mary Ann Liebert, Inc., journals, but if it is necessary, the citation must make it clear that the content is not officially published in a journal, and can only be found on a preprint server.

 

RESEARCH FUNDER COMPLIANCE (FundRef)

Upon submission of a manuscript, the submitting agent will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata to FundRef. The entered information should include funder names, funder IDs (if available), and associated grant numbers.  Special care should be taken when entering this information to ensure total accuracy. (See https://www.crossref.org/services/funder-registry/ for a listing of more than 13,000 international funding agencies.)

GOVERNMENT FUNDED RESEARCH

Journal of Child and Adolescent Psychopharmacology is fully NIH-, HHMI-, RCUK, and Wellcome Trust-compliant.

OPEN ACCESS

Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), the Wellcome Trust, Research Councils UK (RCUK), or Howard Hughes Medical Institute (HHMI), you can find more information below:

  • NIH and HHMI Public Access Policy–In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
  • Wellcome Trust Policy–To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
  • Research Councils UK (RCUK)–To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RCUK.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

POST-ACCEPTANCE / PRODUCTION

All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Depending on the length and complexity of any accepted submission, these steps typically take 3-6 weeks from acceptance.  Changes or alterations to a submission are not permitted after acceptance, but should be addressed in page proofs.

PAGE PROOFS

Page proofs will be sent to the corresponding author as designated in Manuscript Central when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors, if desired, and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors/sources.

AUTHOR RESPONSE TO GALLEY PROOF

  • The corresponding author is responsible for returning corrected galley proofs generally within 72 hours of receipt.
  • If the corresponding author does not respond within that timeframe, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher.
  • If the corresponding author expects to be unavailable during the time the manuscript is in production, the publisher should be provided with an alternate contact. 
  • Only corrections directly related to errors in typesetting and/or layout will be allowed.
  • Any requested changes related to content, or that alter the outcome of a study, will require the approval of the Editor, and may require further peer review.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

POST-PUBLICATION CORRECTIONS

In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration.  After editor approval, alterations will be made to the online version of the article, and if the errors are significant, an official correction statement will be issued.

  • Changes to author affiliations or contact details due to relocation after publication are not permitted.
  • Corrections to meeting abstracts will be made only to the online version.  The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.
  • Correction Statements/Errata to published articles that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).

RETRACTIONS**

The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

**Any publication fees for retracted and/or withdrawn articles are nonrefundable in any circumstance.

STUDY DESIGN AND ETHICS

RESPONDING TO ALLEGATIONS OF POSSIBLE MISCONDUCT

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

DEFINITIONS OF SCIENTIFIC MISCONDUCT

Mary Ann Liebert, Inc., publishers follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  • Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
  • Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
  • Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
  • Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.

RETRACTIONS

The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

ARCHIVING AND PRESERVATION

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Your article will be easily searchable on Google, Google Scholar, and other search engines.

PUBLISHER

Journal of Child and Adolescent Psychopharmacology is owned and published by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801; Tel: 914-740-2100; Email: Info@liebertpub.com; Website: www.liebertpub.com/CAP

The Office of Foreign Assets Control (OFAC) of the US Department of the Treasury administers and enforces economic and trade sanctions based on US foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. (Source: https://www.treasury.gov/about/organizational-structure/offices/pages/office-of-foreign-assets-control.aspx)

Our journal editors welcome contributions from researchers around the world; however, they are also required to follow sanction laws and regulations. Upon the date of this update (August 2020), sanction measures imposed by the United States, United Nations, European Union, and Australia are currently in place against the following countries: Cuba, Crimea, Iran, North Korea, and Syria. Journal editors will treat with caution any submission from a sanctioned country regarding the subject matter and will seek appropriate legal advice from the publisher if necessary.

Papers from sanctioned countries that are submitted to any Mary Ann Liebert, Inc., journal MUST contain a confirmation statement after the conclusion section of the manuscript which indicates that EACH listed author confirms that their research is supported by an institution that is primarily involved in education or research.

For further questions, please contact our Director of Production and Editorial Operations.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.